FDA/AHRQ collaboration
Executive Summary
ODS Deputy Director Anne Trontell will embark on a year-long FDA-sponsored detail beginning in mid-January as a senior advisor in pharmaceutical outcomes research for the Agency for Healthcare Research & Quality. The move will help to improve understanding of the health outcomes of marketed drugs, FDA says, noting the collaboration is part of an effort to foster research partnerships on drug effectiveness and safety. Trontell will promote collaborative research between FDA, AHRQ, CMS, and professional and academic institutions. Office of Pharmacoepidemiology and Statistical Science Deputy Director Jonca Bull will serve as acting ODS deputy director...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.